14.08.2023 – 09:00
Federal Association of Drug Manufacturers (BAH)
Berlin (ots)
“The Health Data Utilization Act offers the opportunity to promote the supply of innovative medicines and digital health applications. However, the new health research data center should definitely abolish existing data monopolies in the health sector,” comments BAH General Manager Dr. Hubertus Cranz presented the draft bill of the Federal Ministry of Health (BMG) on the planned Health Data Utilization Act (GDNG) presented on August 4, 2023. The association hearing on this will take place on Monday. With the law, the BMG wants to improve the use of health data for research and development as well as for health care, especially in the pharmaceuticals sector.
For the BAH, in addition to rapid and coordinated application processing, neutrality when accessing health data is particularly important: “The uniform and common data basis plays a decisive role in achieving negotiation results in order to do justice to the various interests in the field of pharmaceuticals and digital health applications . The recently founded health research data center could make a decisive contribution to improving patient care in a timely manner,” says Cranz.
Access to Cancer Registry Data
In addition, the BAH sees a need for improvement with regard to access to linked data from the health research data center and the clinical cancer register. It should be clearly defined here that pharmaceutical companies also have access to this data, especially in the context of the early benefit assessment. Health care data are currently not sufficiently taken into account in the early benefit assessment of the AMNOG.
Involvement of service providers
The present draft also provides that health and long-term care insurance funds should be authorized to carry out data-based evaluations of the personal health care of their insured persons, to improve health care and to increase patient safety. This gives the health and long-term care insurance companies the new opportunity to address their policyholders on an individual basis about health care. “The topic is of a sensitive nature, since patients usually talk to their doctor or pharmacist about their individual health care. It is therefore essential to involve these service providers in advance in the communication between health and long-term care insurance companies and the patients. This is the only way to ensure trust of patients in the use of their health data will be strengthened,” emphasizes BAH General Manager Cranz.
________________
The Federal Association of Drug Manufacturers (BAH) has the largest number of members in the drug industry in Germany. It represents the interests of around 400 member companies that employ around 80,000 people in Germany. The companies organized in the BAH make a significant contribution to securing the supply of pharmaceuticals in Germany. They provide almost 80 percent of the over-the-counter medicines sold in pharmacies and almost two thirds of the prescription medicines, as well as a large part of the material medical products for patients. There is more information about the BAH at www.bah-bonn.de.
Press contact:
Your contacts in the BAH press office:
Dr. Armin Edalat
press secretary
T. 030 | 308 75 96 – 122
[email protected]
Aileen Wagefeld-Dalitz
Press and public relations officer
T. 030 | 308 75 96 – 123
[email protected]
Berlin office
Federal Association of
drug manufacturer
Friedrichstrasse 134
10117 Berlin
Bonn office
Federal Association of
drug manufacturer
Ubierstraße 71-73
53173 Bonn
www.bah-bonn.de
Original content from: Federal Association of Drug Manufacturers (BAH), transmitted by news aktuell